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ABSTRACT
Background and aim: Chronic hepatitis B is a highly prevalent disease worldwide, leading to seri-
ous consequences if not properly treated. Six treatment options for chronic hepatitis B are currently 
provided by the Brazilian public health system. Telbivudine is a nucleoside analogue that is neither 
included in the Brazilian clinical protocol nor in the therapeutic guidelines for chronic hepatitis B. 
Objective: The aim of this study was to evaluate the cost-effectiveness of telbivudine for the view-
point of the Brazilian public system, comparing it to lamivudine. Methods: A Markov model was 
used to project lifetime complications and costs of treatment with lamivudine or telbivudine for 
chronic hepatitis B in both HBeAg-positive and HBeAg-negative patients. To evaluate disease pro-
gression, probabilities and utilities of virologic response, virologic resistance, compensated cirrhosis, 
decompensated cirrhosis, hepatocellular carcinoma, treatment, interruption of treatment, death and 
seroconversion were collected in systematic reviews. Costs were collected in DATASUS, ABC da 
Saúde and scientific literature. Results: Higher rate of virologic response and seroconversion was 
obtained with telbivudine, and also higher values of quality adjusted life years. However lamivudine 
is associated with lower costs and also lower cost-effectiveness values. The incremental cost-effec-
tiveness ratios for telbivudine, when compared with lamivudine, were US$ 30,575 and US$ 40,457, 
respectively for HBeAg-positive and HBeAg-negative patients. Conclusions: In chronic hepatitis B 
lamivudine is a more cost-effective or even cost-saving strategy when compared with telbivudine.
Keywords: lamivudine; cost-effectiveness evaluation; hepatitis B, chronic.
[Braz J Infect Dis 2011;15(3):225-230]©Elsevier Editora Ltda.
INTRODUCTION
Currently, more than two billion people have 
been infected by hepatitis B virus (HBV), and 
about 350 million remain chronically infected, 
and more than 500,000 people die annually due 
to diseases related to HBV infection.1 It is esti-
mated that chronic hepatitis B (CHB) is among 
the ten leading causes of death worldwide.2 
Individuals with CHB have also increased risk 
of developing liver cirrhosis and hepatocellular 
carcinoma, leading one million individuals an-
nually to death.1,3,4
Treatments of CHB aim to prevent or to reduce 
the development of liver cirrhosis and hepatocel-
lular carcinoma. They also aim viral suppression, 
normalization of alanine aminotransferase (ALT) 
levels, decrease liver damage and seroconversion. 
In Brazil, there are currently six approved drugs for 
use in CHB: lamivudine, interferon alpha (pegylat-
ed and conventional), entecavir, adefovir dipivoxil 
and tenofovir disoproxil fumarate.5-7 Telbivudine is 
a drug used worldwide but not included in Brazil-
ian therapeutic guidelines for CHB.8
Lamivudine was the first nucleoside analogue 
approved for the treatment of CHB, showing to 
be beneficial by reducing HBV DNA levels, nor-
malizing ALT and improving histological liver in 
short-term treatments.9,10 Lamivudine has potent 
action against reverse transcriptase. It inhibits the 
synthesis of HBV DNA from pre-genomic RNA, 
blocking the synthesis of new viral particles.2,11
Telbivudine is a nucleoside analogue with po-
tent activity, selective and specific for hepa DNA 
virus and blocking viral replication. The com-
monly used dose is 600 mg/day.9,12 In the GLOBE 
study, the efficacy of telbivudine and lamivudine 
in HBeAg-positive and HBeAg-negative patients 
with CHB was compared. Telbivudine leads to a 
rapid inhibition of HBV replication and was more 
effective when compared to lamivudine.12,13
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The worldwide increasing technology incorporation, with 
introduction of new equipments, health products and medicines, 
which in the vast majority have high costs, implies to investigate 
whether the improvement in results is significant on the aggre-
gate costs. In particular it is essential that the public manager 
have data for decisions of new technologies to the population.
The introduction of economic evaluation methods and 
the increase in pharmaceutical costs began to contribute 
to the claim for cost-effectiveness evaluations before use 
new technologies.14 Economic evaluation studies also show 
costs among the various treatment options available, con-
tributing to harmonization of the growing health demands.
The aim of this study was to conduct a cost-effectiveness 
analysis comparing treatments with lamivudine and telbivu-
dine for CHB, thus providing information to the Brazilian pub-
lic health system in the incorporation of telbivudine therapy.
MATERIAL AND METHODS
A systematic review was conducted by two independent re-
viewers, to compare efficacy of telbivudine and lamivudine. 
The electronic searches were conducted in the following 
databases: MEDLINE, Cochrane Library, SciELO, LILACS 
and International Pharmaceutical Abstracts. Only studies 
published in English, Portuguese, German or Spanish were 
included. The following words were used in the searches: 
chronic hepatitis B, telbivudine, lamivudine and efficacy. 
Search filters were used to identify RCT. Only studies that 
directly compared the two drugs were included. 
The studies were identified and selected and data were 
extracted using pre-prepared tables. In case of discrepan-
cies in any previous steps, discordant results were resolved 
by consensus. Studies that compared treatments of telbi-
vudine with lamivudine during 24 weeks were included. 
Doses of 600 mg/day of telbivudine or 100 mg/day of lami-
vudine were eligible for inclusion. Data about efficacy and 
safety were extracted from included studies.
For the costs of treatments, direct costs were calculated, 
including drugs, laboratory tests and medical consultations. 
Drug costs were calculated using “ABC da Saúde” tables, 
used in Brazil as a reference, considering that the price of 
telbivudine is not available in public health systems, for not 
having been approved for use in CHB. Other costs, such as 
exams and medical consultations, were calculated from the 
DATASUS price tables of the public health system. 
A Markov model was elaborated in the timeframe of 
ten years, allowing evaluating the possible phases of CHB 
and relevant over time, with each cycle of the model cor-
responding to six months. This model is useful in deci-
sion making, considering the continuing risk over time. 
Moreover, the duration of events that can occur more 
than once during the simulation, is of paramount impor-
tance in this model. To construct the model software was 
used TreeAge ® Pro 2009.
In the model, scenarios were created assuming health 
conditions and situations arising from the use of medicines 
and clinical pathology. The event sequences used were taken 
from studies found in systematic review and adapted with 
support of hepatologists. We adopted the scenario consider-
ing that the sequence of events that may occur are the same 
for both interventions, which varied the probabilities, costs 
and effectiveness of treatments. It was assumed that the age 
of patients that began treatment was 40 years.
It was assumed that all patients entering treatment are 
diagnosed with CHB. The model compares two treatment 
options with telbivudine or lamivudine. Due to the differ-
ent outcomes to treatment in HBeAg positive and negative 
patients, we performed a Markov model for the HBeAg-pos-
itive and another for HBeAg-negative patients. 
We did not evaluate change of therapy.
As the outcome measure, treatment effectiveness was 
determined by the quality-adjusted life years (QALY). This 
measure takes into account both the quantity and quality of 
life resulting from treatment. Quality of life is estimated by 
using instruments to assess the perception of a given health 
condition in a value between two extreme points: 0 (death) 
and 1 (perfect health). This value, known as utility, is multi-
plied by time in which the individual spends in each state of 
health. For each Markov state of the literature, information 
regarding the utility of patients in the state was searched.
A! er defining the health states, the costs for each health 
state were also searched in the literature. These were added 
to the Markov model and added to the costs of treatment 
(with lamivudine or telbivudine).
Sensitivity analysis was performed to determine the robust-
ness of the model by varying the value of some key variables 
used.15 So it may lead to a decrease in the level of uncertainty 
in estimates of costs and their relationship with the effect of 
the intervention. A one way analysis of costs and effectiveness 
(measured by utility of virologic response and seroconversion) 
was performed for both treatment groups, varying them by 
20%. The discount rate was 5% for costs and effectiveness (util-
ity of virologic response and seroconversion).
RESULTS
Nine citations in electronic databases were founded, of 
which four were excluded on the basis of title or abstract. 
The remaining five citations were evaluated by two inde-
pendent reviewers. Among these, three studies were ex-
cluded a! er examination of the full text (different times of 
treatment or comparison to other drugs). The remaining 
two articles were included in our economic evaluation. 
The estimated costs of each treatment are described in 
Table 1, and are calculated for the period of six months, 
which is a Markov cycle. The costs found for each health 
state were fixed to the current value (2010) and calculated 
for each cycle (Table 2).
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We created the following health states in Markov 
model for HBeAg-positive patients: virologic response, 
virologic resistance, compensated cirrhosis, decompen-
sated cirrhosis, hepatocellular carcinoma, CHB-treatment, 
interruption of treatment, death and seroconversion. For 
Table 1. Costs of procedure/drugs per unity and per cycle 
Procedure / Drug Periodicity Cost (US$) Cost per cycle (US$)
Lamivudine 150 mg Daily 4.72 861.35*
Telbivudine 600 mg Daily 17.49 3,191.27*
Hemogram with platelet count Every 3 months 2.48 4.95**
ALT/AST Every month 1.21 7.27**
TSH  Every 3 months 7.96 15.91**
Fasting glucose Every 3 months 1.12 2.23**
Medical visit Every 6 months 6.03 6.03**
ALT, alanine aminotransferase; AST, aspartate aminotransferase; TSH, thyroid-stimulating hormone.
* according ABC tables
** according DATASUS tables 
HBeAg-negative patients the state seroconversion was withdrawn.
It was considered that all patients started treatment in 
the state CHB-treatment. In the next cycle, patients switched 
to other states according to the probabilities found in the 
literature review, described in Table 3.
Table 2. Costs of each health state, annual and per cycle fixed to current values16
Procedure Clinical follow-up Compensated Decompensated Hepatocarcinom Hepatic 
  cirrhosis cirrhosis  transplant
Annual cost (US$) 770.25 976.20 17,293.35 3,741.70 68,609.73
Per cycle cost (US$) 385.12 488.10 8,646.68 1,870.85 34,304.86
Table 3. Probability of reaching each state of CHB
Initial state State reached Range lamivudine  Range telbivudine Reference
 Virologic resistance 0.1188  0.0562 12, 17
 Virologic response 0.4637  0.5186 12, 17
CHB
 CC  0.0999  18
 HC  0.0131  18, 19
 Death  0.0014  1
 Soroconversion* 0.2063  0.2314 12, 17
Virologic Death  0.029  18
resistance HC  0.4782  19
Soroconversion
 CC  0.0391  18
 HC  0.0131  19
 DC  0.05  20
CC Death  0.029  18
 HC  0.071  20
HC
 Transplant  0.0008  20
 Death  0.372  20
 HC  0.025  20
DC Transplant  0.014  20
 Death  0.39  20
Transplant Death  0.15  20
CC, compensated cirrhosis. CHB, chronic hepatitis B; DC, decompensated cirrhosis; HC, hepatocarcinom.
* only for HBeAg positive patients. 
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Table 4. Utility of each disease state
Health state Utility Reference
Transplant 0.5 20
Virologic resistance 0.655 Experts opinion
Virologic response (HBV DNA < 5log10) 0.755 21
Decompensated cirrhosis 0.35 22
Treatment 0.755 21
Treatment interruption 0.8 Experts opinion
Seroconversion 0.755 21
Hepatocarcinom 0.37 22
Compensated cirrhosis 0.7 22
Table 5. Cost, effectiveness, cost-effectiveness and ICER of lamivudine and telbivudine for HBeAg positive  
patients
 Cost Incremental Effect Incremental C/E Incremental (US$) 
 (US$) cost (US$) (QALY) effect  C/E (ICER) 
Lamivudine 19,065  12.79  1,491 
Telbivudine 50,284 31,220 13.81 1.02 3,641 30,575
QALY, quality-adjusted life year; ICER, incremental cost-effectiveness ratio.
Cost-effectiveness analysis
HBeAg positive patients
Lamivudine
Telbivudine
Effectiveness
Figure 1: Cost-effectiveness analysis in HBeAg positive 
patients.
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Cost-effectiveness analysis
HBeAg negative patients
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Figure 2: Cost-effectiveness analysis in HBeAg negative 
patients.
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The utility of patients in each of the health states 
found in the literature is described in Table 4.
Markov models for cost-effectiveness analysis of 
HBeAg-positive and HBeAg-negative patients are rep-
resented in Figures 1 and 2, respectively. 
The effect, cost, cost-effectiveness and incremental cost-
effectiveness ratios (ICER) are described in Tables 5 and 6, re-
spectively for HBeAg-positive and HBeAg-negative patients.
In sensitivity analysis (Table 7), the cost-effectiveness of 
lamivudine was superior to telbivudine in all analysis, em-
phasizing the results robustness.
Cost-effectiveness of telbivudine versus lamivudine for chronic hepatitis B
229Braz J Infect Dis 2011; 15(3):225-230
Table 6. Cost, effectiveness, cost-effectiveness and ICER of lamivudine and telbivudine for HBeAg negative  
patients 
 Cost Incremental  Effect Incremental C/E Incremental 
 (US$) cost (US$) (QALY) effect  C/E (ICER) (US$)
Lamivudine 22,649  10.44  2,170 
Telbivudine 58,619 35,970 11.33 0.89 5,175 40,457
QALY, quality-adjusted life year; ICER, incremental cost-effectiveness ratio.
Table 7. One way sensitivity analysis for costs and 
effects
Variable Basal value Range Value
Cost lamivudine (US$) 897 20% 1,077 
  -20% 718
Cost telbivudine (US$) 3,227 20% 3,873 
  -20% 2,582
Virologic response 0.4637 20% 0.5564 
Lamivudine  -20% 0.3709
Virologic response 0.0562 20% 0.0674 
Telbivudine  -20% 0.0449
Soroconversion 0.2063 20% 0.2475 
Lamivudine  -20% 0.1650
Soroconversion 0.2314 20% 0.2777 
Telbivudine  -20% 0.1851
DISCUSSION
Lamivudine is used for the treatment of CHB for over 20 
years, with demonstrated effectiveness and safety.9,10 How-
ever, many patients suffer some viral mutation and develop 
viral resistance to the drug.11 In recent years, new drugs were 
developed for the disease, providing other treatment options. 
The efficacy and safety of telbivudine for the treatment of 
CHB has been shown previously.12,13 However, when there are 
new drugs to treat a disease, it is of great importance to evalu-
ate its cost-effectiveness, comparing it to existing treatments. 
Due to the widespread use of lamivudine for the treatment of 
CHB, it was used as the standard to be compared to telbivu-
dine to evaluate cost-effectiveness of this study.
When evaluating the effectiveness data of both therapies 
separately, within six months of treatment there are higher 
seroconversion rates and better virologic response of telbi-
vudine, and also lower rate of virologic resistance. However, 
this is not enough for a decision, especially in a disease of 
high prevalence worldwide. In such cases, it is of paramount 
importance that health care managers and physicians have 
information about the cost-effectiveness of available treat-
ments, for a better allocation of available resources.
In the current study, we obtained values of QALY 12.79 
and 13.81 for lamivudine and telbivudine, respectively, af-
ter 10 years of treatment in HBeAg-positive patients, and 
10.44 and 11.33, respectively, for HBeAg-negative patients. 
These values lead us to indicates similar effectiveness of 
both treatments. However, when evaluating the cost-ef-
fectiveness ratios, we found that this ratio is much higher 
for telbivudine, reaching an ICER of over than $ 30,000 
in both, HBeAg-positive and HBeAg-negative patients. In 
such cases, health system and physicians have to assess the 
benefits of each therapy and the available resources to be 
spent on the treatment.
CONCLUSION
In conclusion, in our analysis of clinical and economic out-
comes of lamivudine and telbivudine, for treating HBeAg-
positive and HBeAg-negative patients, both strategies are 
effective, whereas the effectiveness of telbivudine is slightly 
higher than that of lamivudine. However, comparing the cost-
effectiveness, lamivudine is more cost-effective than telbivu-
dine. Managers and professionals have to choose the appro-
priate therapy to patients according to the available budget.
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